Literature DB >> 30393612

LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.

Rachael Chang Lee1, Bibhusal Thapa1, Thomas John1.   

Abstract

Entities:  

Year:  2018        PMID： 30393612      PMCID： PMC6193923          DOI： 10.21037/tlcr.2018.09.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  22 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer.

Authors:  Patrick Micke; Karolina Edlund; Lars Holmberg; Hanna Göransson Kultima; Larry Mansouri; Simon Ekman; Michael Bergqvist; Lena Scheibenflug; Kristina Lamberg; Gunnar Myrdal; Anders Berglund; Annsofie Andersson; Mats Lambe; Fredrik Nyberg; Andrew Thomas; Anders Isaksson; Johan Botling
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

Review 3.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

Review 4.  Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.

Authors:  K A Olaussen; S Postel-Vinay
Journal:  Ann Oncol       Date:  2016-08-08       Impact factor: 32.976

Review 5.  Chromosomal and genomic changes in lung cancer.

Authors:  Marileila Varella-Garcia
Journal:  Cell Adh Migr       Date:  2010-01-07       Impact factor: 3.405

6.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 8.  Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.

Authors:  Maria Bonomi; Sara Pilotto; Michele Milella; Francesco Massari; Sara Cingarlini; Matteo Brunelli; Marco Chilosi; Giampaolo Tortora; Emilio Bria
Journal:  J Exp Clin Cancer Res       Date:  2011-12-29

9.  Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling.

Authors:  Joseph M Foster; Assa Oumie; Fiona S Togneri; Fabiana Ramos Vasques; Debra Hau; Morag Taylor; Emma Tinkler-Hundal; Katie Southward; Paul Medlow; Keith McGreeghan-Crosby; Iris Halfpenny; Dominic J McMullan; Phil Quirke; Katherine E Keating; Mike Griffiths; Karen G Spink; Fiona Brew
Journal:  BMC Med Genomics       Date:  2015-02-18       Impact factor: 3.063

10.  High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.

Authors:  Mir Alireza Hoda; Anita Rozsas; Elisabeth Lang; Thomas Klikovits; Zoltan Lohinai; Szilvia Torok; Judit Berta; Matyas Bendek; Walter Berger; Balazs Hegedus; Walter Klepetko; Ferenc Renyi-Vamos; Michael Grusch; Balazs Dome; Viktoria Laszlo
Journal:  Oncotarget       Date:  2016-03-22
View more
  1 in total

1.  Astragaloside IV sensitizes non-small cell lung cancer cells to cisplatin by suppressing endoplasmic reticulum stress and autophagy.

Authors:  Song-Tao Lai; Yan Wang; Fei Peng
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 3.005
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.